KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy-Reference-Cited by-同舟云学术

KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy

Published:2018-05-29 Issue:41 Volume:9 Page:26279-26290
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Bruera Gemma¹²,Pepe Francesco³,Malapelle Umberto³,Pisapia Pasquale³,Mas Antonella Dal⁴,Di Giacomo Daniela¹²,Calvisi Giuseppe⁴,Troncone Giancarlo³,Ricevuto Enrico¹²

Affiliation:

1. Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L'Aquila, L'Aquila, Italy

2. Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy

3. Department of Public Health, University Federico II, Napoli, Italy

4. Pathology, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L'Aquila, Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Impact of Primary Tumor Sidedness in Stage III Colorectal Cancer: Real-World Evidence from a Brazilian Cohort;Clinical Colorectal Cancer;2023-12

2. Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer;Current Issues in Molecular Biology;2023-09-26

3. Metastatik Kolorektal Kanserli Hastalarda KRAS/NRAS Gen Mutasyon Profilleri;Kocaeli Üniversitesi Sağlık Bilimleri Dergisi;2022-09-30

4. Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases;BMC Cancer;2022-06-16

5. Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report;Frontiers in Oncology;2022-04-07